Advanced Biomed Inc. ADVB
- Market cap
- $10.4M
- P/E
- 1.3×
Follow ADVB
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | 5.60 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | — | 82.00 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 40 | 31 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | — | Revenue | |||
| — | — | — | — | — | — | — | — | — | — | Gross Margin | |||
| — | — | — | — | — | — | — | — | (3) | (3) |
EBT
|
|||
| — | — | — | — | — | — | — | — | 0.00% | 0.00% |
EBT Margin
|
|||
| — | — | — | — | — | — | — | — | (3) | (3) |
Net Income
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Depreciation
|
|||
| — | — | — | — | — | — | — | — | 0.00 | 0.00 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | — | — | (2.78) | (3.20) |
Earnings/Sh
|
|||
| — | — | — | — | — | — | — | — | (2.13) | (5.68) |
Cash Flow/Sh
|
|||
| — | — | — | — | — | — | — | — | (0.07) | (0.03) |
Capex/Sh
|
|||
| — | — | — | — | — | — | — | — | (2.20) | (5.71) |
Free CF/Sh
|
|||
| — | — | — | — | — | — | — | — | 1.66 | 3.39 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | — | — | 1 | 1 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | — | PE Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PS Ratio | |||
| — | — | — | — | — | — | — | — | — | — | PB Ratio | |||
| — | — | — | — | — | — | — | — | — | — | EV/Sales | |||
| — | — | — | — | — | — | — | — | — | — | EV/FCF | |||
| — | — | — | — | — | — | — | — | (2) | (6) |
Op' Cash Flow
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Capex
|
|||
| — | — | — | — | — | — | — | — | (2) | (6) |
FCF
|
|||
| — | — | — | — | — | — | — | — | 0 | 3 |
Working Cap'
|
|||
| — | — | — | — | — | — | — | — | — | — | Total Debt | |||
| — | — | — | — | — | — | — | — | (3) | (3) |
Net Debt
|
|||
| — | — | — | — | — | — | — | — | 2 | 3 |
Sh' Equity
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (59.40%) |
ROA
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (329.11%) |
ROIC
|
|||
| — | — | — | — | — | — | — | — | 0.00% | (126.79%) |
ROE
|
|||
Advanced Biomed Inc. peers in Diagnostics & Research
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| BIAF bioAffinity Technologies, Inc. | $9.0M | 0.0× | Compare |
| NDRA ENDRA Life Sciences Inc. | $8.9M | 0.0× | Compare |
| XWEL XWELL, Inc. | $7.6M | 0.0× | Compare |
| PMD Psychemedics Corporation | $15.7M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| TTOO T2 Biosystems, Inc. | $6.5M | 0.0× | Compare |
| DMTKQ DermTech, Inc. | $3.3M | 0.0× | Compare |
| ISPC iSpecimen Inc. | $3.1M | 0.0× | Compare |
| NOTVQ Inotiv, Inc. | $2.8M | 0.0× | Compare |
Advanced Biomed Inc. (ADVB) key facts
- Advanced Biomed Inc. (ADVB) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
- As of September 25, 2026, ADVB traded at $6.38, a market capitalization of $10.4 million.
- Return on equity was −126.8% and debt-to-equity 0.00.
Advanced Biomed Inc. (ADVB) Latest News
13 Feb
Advanced Biomed Inc. has announced a 120-case feasibility study in collaboration with Chi-Mei Medical Center to validate its A+PerfusC™ platform, which integrates perfusion and 3D cell culture for precision medicine and drug discovery. This study aims to enhance the platform's effectiveness and applicability in the medical field. The feasibility study represents a significant strategic move that could enhance product validation and market positioning.
30 Dec
Advanced Biomed Inc. has announced the disposal of its Hong Kong subsidiary as part of a strategic decision to streamline operations and focus on core business areas. The move is expected to enhance the company's financial position and operational efficiency. The disposal of the subsidiary may moderately influence financial performance and operational focus.
19 Sep
Advanced Biomed Inc. has launched A+PerfusC™, an integrated perfusion 3D cell culture platform designed to enhance precision medicine and drug discovery. This innovative platform aims to improve the efficiency and effectiveness of cell culture processes, potentially leading to better therapeutic outcomes and advancements in research methodologies. The launch of A+PerfusC™ represents a significant strategic move that could enhance product offerings and competitive positioning in the biotechnology sector.
7 Mar
Advanced Biomed Inc. (NASDAQ: ADVB) has closed its initial public offering of 1,640,000 shares at $4.00 per share, raising $6.56 million. The shares began trading on March 6, 2025. The company plans to use the proceeds for clinical research, marketing, and general working capital. An underwriter option allows for an additional 246,000 shares to be purchased within 45 days. The offering was conducted under a registration statement declared effective by the SEC on February 11, 2025. The IPO and subsequent funding will significantly enhance the company's capabilities and market presence in the biotechnology sector.
6 Mar
Advanced Biomed Inc. has announced the pricing of its initial public offering (IPO), setting the price at $15 per share. The company aims to raise approximately $100 million through the offering, which is expected to enhance its financial position and support future growth initiatives. The IPO is anticipated to attract significant investor interest, reflecting confidence in the company's potential in the biomedical sector. The IPO represents a major strategic move that could significantly alter the company's trajectory and investor sentiment.